ARNI Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:25):

Stats
Tagesvolumen	3 500.00
Durchschnittsvolumen	62.00
Marktkapitalisierung	177 659
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2013-01-25	Kariv Tomer	Buy	0	Common Stock
2013-01-25	Kariv Tomer	Buy	0	Common Stock
2013-01-25	Kariv Tomer	Buy	0	Common Stock
2016-08-15	Belldegrun Arie	Buy	714 285	Common Stock
2016-08-15	Belldegrun Arie	Buy	357 142	2016 Series F Warrants (right to buy)

INSIDER POWER
0.00
Last 89 transactions
Buy: 17 291 951 \| Sell: 681 614

Volumen Korrelation

Lang: -0.51 (weak negative)

Kurz: -0.35 (neutral)

Signal:(10.878) Neutral

Arno Therapeutics, Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Arno Therapeutics, Inc. Korrelation - Währung/Rohstoff

0.00
( neutral )

-0.09
( neutral )

Arno Therapeutics, Inc. Finanzdaten

Annual	2022
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$0

FY	2022
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$0

FY	2015
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-0.560

FY	2014
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$0.380

Financial Reports:

No articles found.

Arno Therapeutics, Inc.

Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.